Clal Insurance’s Teva Pharmaceuticals TEVA Stock Holding History

Clal Insurance’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3M	Buy	+29,050	New	+$935K	0.07%	93
2025 Q2	–	Sell	-60,000	Closed	-$2.64M	–	216
2025 Q1	$2.64M	Buy	60,000 +44,623	+290%	+$797K	0.03%	81
2024 Q4	$4.69M	Buy	+15,377	New	+$280K	0.04%	76
2024 Q2	–	Sell	-72,500	Closed	-$11.8M	–	146
2024 Q1	$11.8M	Buy	+72,500	New	+$914K	0.13%	74
2023 Q4	–	Sell	-1,250	Closed	-$40K	–	139
2023 Q3	$40K	Buy	+1,250	New	+$11.6K	﹤0.01%	123

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clal Insurance's TEVA Position: Q1 2026 in Review

Clal Insurance increased its Teva Pharmaceuticals (TEVA) stake by 2.8% in Q1 2026, buying an estimated $33.5M and bringing the position to 38,446,506 shares worth $1.15B. The position accounts for 6.91% of the portfolio, ranked #4.

Clal Insurance first reported a position in TEVA in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.17B in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Clal Insurance held 38,446,506 shares of Teva Pharmaceuticals worth $1.15B as of Q1 2026.
Clal Insurance bought 1,042,400 Teva Pharmaceuticals shares in Q1 2026, an estimated $33.5M.
Teva Pharmaceuticals made up 6.91% of Clal Insurance's portfolio in Q1 2026, its #4 holding.
Clal Insurance first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
Clal Insurance's Teva Pharmaceuticals position peaked at $1.17B in Q4 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Clal Insurance's 13F filing for Q1 2026, filed 12 May 2026.